Kymera Therapeutics (KYMR) announced its anticipated 2026 preclinical and clinical milestones across its oral immunology pipeline. Key highlights: KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027; KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027; KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26; Advancing at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Advances KT-621 Into Mid-Stage Asthma Trial, Setting Up a New Catalyst for KYMR Investors
- Kymera Therapeutics downgraded at Wolfe ahead of ‘uneventful year’
- Kymera Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
- Kymera Therapeutics falls -4.0%
- Kymera Therapeutics price target raised to $117 from $80 at B. Riley